Robert Friel: I think our view is it go to 100, but its probably going to take 18 months to two years to get fully implemented. As you know the law was suppose to be effective at the first of this year, but I think our view its taken some time to get all the labs setup to be able to do that and so I would say the enforcement is fairly lacks, but I would say probably late ’16 is our best guess of when that occur and probably what you will see is it will occur first on the east coast and you will see it move it across to the west. But we’re starting to see as I think if we have mentioned on the last call, we saw the move from sort of the regional governments to the federal government and while we think that's delayed it a bit in the implementation which you will see is bigger tender and we’re starting to see that coming out and as sort of mentioned in the prepared remarks we feel good about our ability to win share there. With regard to it sort of the border China, I would say first all, we continue to believe that both access to healthcare and the clean water and food will be high priorities and continue to strong organic growth, so I would say we continue to feel like high single-digits probably make sense for us for 2015, and we just go buy end market for us diagnostics, I think Andy talked about this continue to be strong we saw good double-digit growth in diagnostic supported by [audio gap] three pieces of the business, newborn, infectious disease and blood screening. On a research side also pretty good growth there and it was sort of mid-single maybe little bit better than that and environmental was up low single and what we saw was really almost a tale of two cities. In the area food and environmental, we saw strong growth sort of mid-teens and in the area of sort of more industrial, we actually saw some headwinds there from the stand-point that they are -- our business there was not significant decline in the quarter. So we just sort of put really together you saw environmental in the sort of low single-digit.
Robert Friel: Thank you, first of all, we feel good about the pipeline I think our hope and expectation is -- we able to do something roughly toward the end of the year. It’s always difficult to predict those types of things, but I think we feel like, we will be able to put some capital to use here on the M&A, which I would say we have a preferences deployed in that matter, but if we find ourselves in a situation where we are unable to do that for let say for a period of time then we got to probably do share buybacks.
Robert Friel: Yes, we mentioned last quarter I mean water partnership I really think that is more of a longer term strategic move, I think is a number of reasons to do that one was, first of all enable our partners to simply their workflow around sort of one software which is in power, it allows us to focus our resources in areas where we can be more differentiated and hopefully it allows us to drive some incremental revenue by first of all supplying waters LC products to some of our customers maybe driving more incremental products by allowing us to package arranges with our customers where there is multiple analytical techniques and also was getting GC on in power I think there is an opportunity to hope for the -- to sell more into the pharmaceutical industry. Having said that in the short term there is some investment, there is clearly some disruption, there is training required of the sales people, so as I think we mentioned last quarter, we don't really expect to see much of an impact in 2015, and really look towards ‘16 and post to really drive some incremental revenue growth.
Robert Friel: Well, I would say those are couple of things we sort of mentioned affect Japan still seems to be difficult to predict on the academic funding side. Well, the budgets been improved our experience has been that’s been sort of spotty in challenging. So well, it’s a not a big part of our business it’s something that we’re a little cautious about. I’d say the other area that we’re cautious about is on the medical imaging side and we’re seeing some of the revenue challenge is there particularly in the back half. So that was other two areas that I would say we’re little concern. The medical imaging is probably not macro, it’s probably more customer ordering patterns. But I would say on the Japanese side that’s macro indicator. And I would say the other one I would probably put out or again small for us, but obviously the economic condition in Brazil is challenging. So those are two I would expect on the emerging markets that we’re just looking at order and patterns we’re little concern about.
Robert Friel: Well, I would say we were pleasantly surprised on the box side. I mentioned some of the new products, but if you look at our cellular imaging, the microfluidics and automation we saw very strong growth there. So we are pleased with that service also did well OneSource at a strong quarter and I would say the reagents was just sort of laagered in the quarter.
Robert Friel: See in our opinion there is a lot of debate on this internally is any point we do this every six year. So I would say this is under core competency I was trying to predict what the impact will be. But our viewer is even when you look at our reagent business. A lot of our business is in sort of daily or weekly orders. Even though is look at the newborn screening side, it sort of bundle purchases. So I would say we’re enabling we’ll be conservative year, but we’re assuming that we’re not going to see a significant pick-up from the additional days, particular when you look at the how they fall within the calendar.
Robert Friel: So I would say the answer your first question is yes. We’ve assume fairly modest revenue for Japan for the remainder of the year. And I would say beyond 2015 will just sort of assess there when we get there. I mean is it fair assumption to say that some point the funds will be released and maybe we’ll see a catch up. But I guess we’ll just sort of call that as we get in the ’16, but our assumptions for the remainder of ’15 is that we’ll continue to see challenges and we’ve got basically no growth assumes for the remainder of the year.
Robert Friel: So I would say, it’s a little bit of both. I mentioned this quarter that we got our GSP which is are automated platform certified by CFDA. And I think that’s allowing us to obviously sell more those and penetrate by allowing in automated platform, it’s allowing some of the areas within China to expand our menu. And so it’s a combination of the menu expansion as well as adoption. But I would tell you right now is that China is probably close to 85% adopted so we have been pleased to see that good portion of the children in China now been screened.
Robert Friel: I would say China, no; Japan, yes. And I would say the offsets have been a little bit on the pharmaceutical and research side. And we have seen clearly some growth there and again some of that is I think new products and we believe our execution within the combined entity now, some of that is clearly a stronger market. So I would the strength on the research side is offsetting some softness in Japan and Brazil. But again just to reiterate, Japan for us is probably going to be somewhere around 2% to 3% of revenue. So it's not a huge number.
Robert Friel: No, I think it's been usual I mean if we look at the half I mean we feel pretty good about where we are right now, I mean the organic growth is particularly, if you look at Q2 came in a little bit at the high side. We are looking at a backhit that we feel pretty good about, we are getting good traction in the new products. So I think we are still moving forward from an investment perspective and we monitor it as we see bookings from it during the quarter.
Robert Friel: I think if you look at it on a constant currency basis we were 50 basis points, which is a little bit more than we have seen historically, a large piece of that some productivity initiatives, we put in place some of those items, supply chain we have talked about that before. We are starting to see some traction there. And that was enough to offset basically inflation in a slightly non-GAAP mix. So I think we feel pretty good about our ability to sustain it going forward as we continue to get traction with some of these initiatives. And then some of those same people are working at initiatives around the SG&A piece. So we hope to drive productivity improvement on both groups and operating margin.
Robert Friel: Well, I mean place that we saw sort of across the globe is I think when you talked about all the regions sort of in the 4% to 5% range which was great from an organic perspective maybe just to give you some color inside that if you look we are seeing Asia, but if you talk about China, Indian career was strong, they were double-digit as well, Japan obviously was within we talked about that. And so I would say within the U.S. we saw a good growth on the research side as sort of alluded to that. But again it was pretty broad based.
Robert Friel: So on a chromatography side I guess I -- liquid chromatography side actually is a headwind in the quarter, because you can imagine as we transition over the ability to continue to sell on the chromatography is challenging so if anything it was a little bit of a headwind on the gas chromatography side, we do expect in the future to be able to hopefully sell some incremental products there but I would say not noticeable in future. So again if your overall the transition in a short term is going to be a little bit of a headwind but obviously we think it won’t it makes a lot of sense and hope we drive some good incremental revenues as well as I think its roughly it will be helpful from our customer perspective.
Robert Friel: On caliper side, and I think as we talked about this we continue to see a little bit of a headwind every quarter at some of those royalties roll off and I think in this quarter as well there is a little bit of headwind of a couple of million dollars and that will probably continue to probably this year maybe third quarter this year.
Robert Friel: I think our view as -- that's a business that shouldn’t probably grow mid single-digits when we look at the sort of adoption rate of digital and x-ray and then the growth prospects with our CMOS business, I think unfortunately we’ve had a situation where some of our customers most notably of -- so built some inventory and start work out off a little bit as you know this is the one business in PerkinElmer really the only business in PerkinElmer where we’re component supplier as compared to sort of an end system supplier so we’re at a little bit of the mercy of the customers and sort of how well they are able to sort of predict their end market demand and so I think that's why you see some of these lumpiness, orders, in hindsight they are artificially strong because our customers are sort of building inventory and then we have to work some of that off and so I agree with you its clearly more lumpy than we would like I think the underlying market is probably not as lumpy as that but again being a component supplier it makes a little challenging.
Robert Friel: Paul, I mean it depends the time horizon we’re talking about here but I think ultimately we like to see this business get up and 17%, 18%, obviously that's going to take some time to do that but we look at the opportunities within this business and I think one of the big drivers will be and we’ve talked about this in the past as we’ve got a get a greater consumable component to the business and something that the team is working on but I think for us to those types of operating margins, it will take a better mix between instruments and consumables.
Robert Friel: Yes, so one source was up double-digits, in the teens, we continue to see good progress there and I will be like to do is trying to pull in more consumables that are supportive of our instruments in some cases may you have to be on others, but I think because we have the one source engineers in the lab the ability that sell consumables, present some opportunities for us and so some of that organically but I think a lot of we’ll have to be done inorganically.
Robert Friel: Yes, I would see in the most recent Q2 there is minimal benefit on the environmental side, most of the new products were the ones that were launch late ‘14, early ‘15 on the human health side, and we’re starting to see some good traction in this, you can appreciate a lot of times when you come out with these new products it will take a quarter or two to really get some traction in the market place. So minimal impact in Q2, I think you will see the majority in the back half what we’ve said with new products for the full year it was [indiscernible] made it in the 30 to $35 million impact with all company, I think we feel very good about that and just expect will be at high end and maybe even higher than that and so rather get into specific products I would just say we continue to feel very good about the progress and I would say we’ve not be surprised to do better than hop into the range here.
Robert Friel: Well, I think when you think about imaging is an important component of what we do, so if you think about it sort of high level, where I think about PerkinElmer, we take samples we do take in analysis and then we provide answers and knowledge and so anything we can do to continue to drive our capabilities around the ability to [indiscernible] image I think its helpful and so leveraging that capability across as many end markets as possible I think its helpful.
Robert Friel: I think when we went into the year, we saw that and Environmental was up low single-digits and we saw little bit of improvement here relative to that in the second quarter. So what our expectation in the back half is similar to what we saw so to low single.
Robert Friel: I mean what I would say is all three components in China did very well, I mean if you look at the growth rate I mean clearly the blood screening is growing much faster but its all of a very low base, I don't know how meaningful that is but I would just say if when you look at double-digit growth in China you see that across all components. So its again fairly broad based.
Robert Friel: So specifically with blood screening, there have been five companies that have been approved by the Chinese government that can provide products for new clinic asset blood screening. Two of them are international and three of them are considered local Chinese. We are considered one of the local Chinese, because we ended this business through the acquisition of a Chinese company. One of the things we actually had some discussions with the government officials at the time with the acquisition that was clear that we will be treated as a local Chinese company. Because again what there, I think most interested in is employment and because the products are developed in Made in China and obviously with Chinese employees I think that’s my sense is that’s why we get the designation as we go.
Robert Friel: So I would say in the newborn side, no. We’re not seen much of push there. I think in the NIPT, I think still challenging from a cost perspective, so you’re not seeing huge adoption. However, we do believe that the NIPT market will be very attractive in China eventually, because there has not been a very large biochemical screening business. So consequently they don’t need to sort of swap, so they skip generation of products. And so we do think once the costs it’s down to an acceptable level within China, we think that’s going to be an attractive market.
Robert Friel: I think, I mentioned so if you look on a constant currency basis, we’re about little over 10% up for the year. And our goal is eventually get R&D to be about 6% of revenue. And so we’ll look it sort of move that up depending on how we feel about revenue and profitability. But that’s our goal, our goal is get up to 6% of revenue and then when you consider effect it service is about 25% that would take us to about 7.5% on product and we think that’s probably the right level. It varies a little bit by – it varies in some cases a lot by business and obviously application, but we think for PerkinElmer a sort of awaited average of 7.5% on product is probably good level.
Robert Friel: Well, it’s a little difficult to parts that out. I would say, my sense is probably more demand right now, because we feel good about the combination with informatics in the product side of the business. I mean, it’s difficult to say that because we just at the beginning of the year that we saw material impact in Q2. So but I mean, I think our expectation is and we’re having some good discussions with the customers and clearly what it’s allowing us to do is where were strong as an informatics customers to bring in OneSource in vice versa. And so I think going forward we’ve got some, where we’re optimistic, but I would say the impact in Q2 I would say it’s probably fairly minimal. But the reason why it’s hard to part out, right now as I said, I mean it’s a combined sales force So it's a little difficult to keep that way.
Robert Friel: About 4, I mean as there is a couple as I mentioned with JSPs now are and expanding that so we’ve got some that high single-digits but on average its probably about four.
Robert Friel: I think those things are always difficult to do, because you are trying to predict the uptake but I think it goes up, it’s a acquisition of how quickly, I mean the other opportunity is mass specs goes into that market place as you know you have the ability to jump up fairly significantly but I would say in two years, I’ll be disappointed for not pushing low end to double-digits.
Robert Friel: I would think in the diagnostic area, its relatively small and we’re starting to make some enrolls into the applied area but I would still say relative basis, still relative in minor.
Robert Friel: I would say we’ve been a little disappointed in the uptake there and I think we’ve talked about this in the quarter as well, I mean I think we’ve found a challenging from a pricing perspective where is some of the competitors are out there guarantying a low number relative to out of pocket and we find that to be challenging from a regulatory perspective, I’ll just put it that way. And so consequently we are having a difficult time finding it at least within our business practices to be competitive.
Robert Friel: Yes, so I would say that there are couple of the Opera Phenix which is a imager, a high-content imager, we continue to see very strong adoption I think we’ve got a nice value preposition here for the customer I think we’ve gain a nice value proposition there for the customer, I think we very pleased with that. I spiked out the new microfluidics which is a larger touch, I think we’re seeing some nice adoption there in the area of biotherapeutics and also on the NGS side, because it goes into sort of quality control on the sample prep and obviously with the ramp up in all the NGS, that’s pointing nice demand as well and the other area is we’ve seen good growth in-vivo. So a number of areas that we’ve been very pleased with on the research side.
Robert Friel: So that’s in area we have been sort of investing both in sort of mostly in people and I’d say we’re making grew progress there, we still got way to go, I mean I still, these people are a difficult to find and attract, but I’d say we’ve made some progress there. I would say in summary we feel very good about our capabilities clearly on the analytic side and the visualization side, I think we’re very strong in the chemistry by the chemical side of things. I think the areas where we need to invest a little bit is on the biological side and as we’ve talked about in the past we’re trying to build a lot of capability in the cloud. But I think we feel good about the progress we’re making, I think they’re still more to do. I think the other thing is when you go to around the place is like ASNS or ACC. You continue to reinforce the importance of informatics and the capabilities that we’re building, because clearly and whether it’s research environmental or diagnostic it’s going to become increasing more important.
Robert Friel: So I mean, I think we view as an opportunity within emerging markets, I think the challenge for us has been trying to find a technology that is both sort of sensitive and output at the same time cheap enough and so the users low energy and all the needs that are require to work in the environment of emerging market. So I think it has a potential to be very attractive market. But I think it’s got to be the right product, the right technology and up at this point this it’s been challenging sort of find the right one that on.
Robert Friel: Well, thank you very much. And I want to appreciate everyone taking the time this morning. We feel good about our progress year-to-date and believe we are well position to deliver on our full year financial commitments and continue to make progress on our strategic priorities. Thank you for your interest in PerkinElmer and have a great evening.
Andy Wilson: Sure, well I think half way through the year, I feel like we’re on track, we were looking at $10 million boggy year-over-year. We aggregated the first half at 6 million, I think we’re started to gain some momentum the roll out is now global and we’re seeing a fairly significant uptake with the organization around it we are spending a lot of time now on upside services, and I think what you are going to see is the impact of that not only on the expense side, but you should start to see on the working capital side, because I think if you look at our payables we saw little improvement in accounts payables and part of that's due to our renegotiation, some contracts with vendors as part of this indirect spin process. So I think we feel like that we’re pretty much on track I would say.
Andy Wilson: I think you also see a little bit of the issue in working capital, we’ve seen as increased inventory and as I explained some of the new products, this would be a part of that as we start to build the channel with some of the new LCs.
Andy Wilson: No it was not supply chain effort, it was actually, it was the new product launches that we put out it at Pittcon then demo inventory and the build around that, what I called out on a first quarter I believe was around Ocean freight. And that ocean freight is the build of inventory that basically stay but it happened in the first quarter, so that -- and that allows us to reduce our overall freight cost, so I think from a P&L perspective it's a good thing, but there is a pickup of inventory as you put the stuff and ship it overseas.
